<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006477</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-13001</org_study_id>
    <secondary_id>EORTC-13001</secondary_id>
    <nct_id>NCT00006477</nct_id>
  </id_info>
  <brief_title>Mistletoe Lectin in Treating Patients With Refractory Advanced Solid Tumors</brief_title>
  <official_title>Phase I Clinical Trial of Recombinant Viscumin (rVISCUMIN, rMISTLETOE LECTIN, rML) Administered Twice Weekly by the Subcutanous Route in Patients With Solid Tumors After Failure of Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Mistletoe lectin may slow the growth of cancer cells and be an effective treatment&#xD;
      for solid tumors.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of mistletoe lectin in treating patients&#xD;
      who have refractory advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose and dose-limiting toxicity of mistletoe lectin&#xD;
           (recombinant viscumin) in patients with advanced solid tumors who have failed standard&#xD;
           therapy.&#xD;
&#xD;
        -  Determine the optimal biologically active dose of mistletoe lectin based on analysis of&#xD;
           specific biological surrogate markers, including plasma cytokine levels and peripheral&#xD;
           counts of activated immune cells and immunological stimulation at the RNA level of the&#xD;
           immune cells.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
        -  Determine whether induction of antibodies against mistletoe lectin occurs in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine whether modification of endothelial parameters occurs in patients treated with&#xD;
           this regimen.&#xD;
&#xD;
        -  Determine the objective response rates in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study.&#xD;
&#xD;
      Patients receive mistletoe lectin (recombinant viscumin) subcutaneously twice weekly. Courses&#xD;
      repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 1-6 patients receive escalating doses of mistletoe lectin until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose at which at least 2 of 3&#xD;
      or 2 of 6 patients experience dose-limiting toxicity. Additional patients are treated at the&#xD;
      highest dose level immediately preceding the MTD.&#xD;
&#xD;
      Patients are followed every 3 months until disease progression or initiation of another&#xD;
      therapy.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 25 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">26</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>mistletoe extract</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically proven progressive advanced solid tumor that is not&#xD;
             amenable to standard therapy (i.e., resistant to standard therapy or for which no&#xD;
             standard therapy exists)&#xD;
&#xD;
          -  No clinically symptomatic CNS involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT less than 2 times ULN (5 times ULN if liver metastases present)&#xD;
&#xD;
          -  Alkaline phosphatase less than 2 times ULN (5 times ULN if liver metastases present)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.4 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No ECG abnormalities of clinical relevance&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No severe or unstable systemic disease or infection&#xD;
&#xD;
          -  No circumstances (e.g., alcoholism or substance abuse) that would preclude study&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior immunostimulating substances (e.g., biologic response&#xD;
             modifiers or colony-stimulating factors)&#xD;
&#xD;
          -  No concurrent immunostimulating substances (e.g., biologic response modifiers or&#xD;
             colony-stimulating factors (except in life-threatening situations))&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior systemic steroids&#xD;
&#xD;
          -  At least 4 weeks since prior hormonal therapy&#xD;
&#xD;
          -  No concurrent systemic steroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior mistletoe preparations&#xD;
&#xD;
          -  At least 4 weeks since prior investigational treatment&#xD;
&#xD;
          -  No other concurrent anticancer agents&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steinar Aamdal, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Norwegian Radium Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum der J.W. Goethe Universitaet</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norwegian Radium Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>N-0310</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Norway</country>
  </location_countries>
  <results_reference>
    <citation>Bergmann L, Aamdal S, Marreaud S, Lacombe D, Herold M, Yamaguchi T, Wilhelm-Ogunbiyi K, Lentzen H, Zwierzina H; European Organisation for Research and Treatment of Cancer. Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001). Eur J Cancer. 2008 Aug;44(12):1657-62. doi: 10.1016/j.ejca.2008.05.005. Epub 2008 Jul 2.</citation>
    <PMID>18602257</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>November 6, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 17, 2012</last_update_submitted>
  <last_update_submitted_qc>July 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

